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Rhodococcus-equi speciﬁc hyperimmune plasma
decreased rhodococcal pneumonia severity in
newborn foals after experimental infection
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Veterinary Science, University of Kentucky, Lexington, KY
40546-0099Rhodococcus equi is the most common cause of pneumonia in
young foals. As a vaccine is not available, farms with an endemic
problem rely in the use of R. equi speciﬁc hyperimmune plasma
(HIP), although the efﬁcacy of this practice remains uncertain. The
objective of this study was to evaluate the ability of a commer-
cially available HIP to prevent clinical rhodococcal pneumonia in
neonatal foals after experimental challenge. Nine foals were given
intravenous HIP after birth while 9 remained as controls. Within
the ﬁrst week of life, all foals received 103cfu/foal of pathogenic R.
equi intratracheally as previously described (Sanz et al 2013).
Thereafter, foals were monitored for 8 weeks and samples were
collected during that period as described before (Sanz et al 2013).
VapA-speciﬁc IgG and IgG subclasses in serum and in bron-
choalveolar lavage ﬂuid (BALF) were evaluated using ELISA (Sanz
et al 2014). One foal in the HIP group and 4 in the control group
developed clinical pneumonia; however, the power of the study
was too low to detect a statistical signiﬁcant effect of treatment.
HIP foals had signiﬁcantly lower weekly ultrasonographic scores
(p<0.05, Figure 1), lower white blood cell counts (p¼0.03),
platelet counts (p¼0.01) and ﬁbrinogen concentration (p¼0.01)
than controls. Serum VapA-speciﬁc IgG, IgGa and IgGb were
signiﬁcantly higher in HIP foals and IgGa and IgG(T) signiﬁcantly
increased (p<0.001) over time only in control foals. VapA-speciﬁc
IgG (p¼0.02) and IgGb (p¼0.04) were signiﬁcantly higher in BALF
of HIP foals. In this study, HIP administration decreased severity of
pneumonia, which reduced the need for antimicrobial treatment.
Antibodies present in HIP transferred to BALF of foals shortly afterFigure 1. Thoracic ultrasound score (diameter, cm) of neonatal foals
experimentally challenged with R. equi after administration of HIP (black) or
nothing (gray). The horizontal line within the box represents the median
and the ends of the box the 75th and 25th quantiles respectively. The asterisk
(*) indicates that values signiﬁcantly differ (p<0.05) from the pre-challenge
(w1) value for each group. The hash (#) indicates that values signiﬁcantly
(p<0.05) differ between groups at a given time point.HIP administration. VapA-speciﬁc IgG(T), which increases with R.
equi infection, was only elevated in control foals. In conclusion,
while infection after challenge was not prevented by R. equi-
speciﬁc hyperimmune plasma (HIP) administration, severity of
clinical pneumonia decreased.References
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Variation of anti-Rhodococcus equi VapA speciﬁc IgGs
among eleven different lots of one commercially
available Rhodococcus equi speciﬁc hyperimmune
plasma product
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Lexington, KY 40511Rhodococcus equi, a gram-positive facultative intracellular
pathogen, is the most common cause of pneumonia in foals
between 3 weeks and 5 months of age. To date, there is no
vaccine available, and mass treatment of foals with antibiotics
may incur in serious long-term effects and is strongly discour-
aged. Therefore, on farms with enzootic rhodococcal pneu-
monia, prophylaxis measures rely greatly on the administration
of R. equi speciﬁc hyperimmune plasma (HIP). The efﬁcacy of R.
equi HIP in controlling disease due to either natural or induced
infection has been historically controversial. Variability in
plasma products may have played an important role. Recently,
four commercial R equi HIP products were evaluated for their
concentrations of Vap-A speciﬁc immunoglobulin G (IgG) and
IgG subclasses. Marked variation was observed between
different products, and different lots from the same product,
which may have important clinical and ﬁnancial consequences.
In order to further investigate the amount of variation in a
commercially available plasma product, and its relation with
speciﬁc R. equi IgG in the recipient foals, a foal population from a
local farm that routinely receives R. equi speciﬁc HIP due to
enzootic R. equi pneumonia, was selected. Exclusion criteria for
the foals were documented failure of passive transfer, and clin-
ical disease other than pneumonia. All newborn foals received 1
liter of intravenous R. equi HIP1 within 24 hours after being born.
HIP samples (n ¼ )were collected at administration time. Serum
samples were collected from all healthy foals (n ¼ ) and their
respective dams (n ¼ ) within 24 and 48 hours after HIP
administration. All samples were archived in -20C for batch
analysis with previously validated ELISA for equine anti-VapA
total IgG and IgG(a), IgG(b), and IgG(t). Eleven different HIP lots
